New discoveries in chemical research and development in 2021. The appropriate choice of redox mediator can avoid electrode passivation and overpotential, which strongly inhibit the efficient activation of substrates in electrolysis. In a patent, 5908-62-3, name is 1,1-Dioxo-isothiazolidine, introducing its new discovery. name: 1,1-Dioxo-isothiazolidine
Targeting the capsid protein of hepatitis B virus (HBV) and thus interrupting normal capsid formation have been an attractive approach to block the replication of HBV viruses. We carried out multidimensional structural optimizations based on the heteroaryldihydropyrimidine (HAP) analogue Bay41-4109 (1) and identified a novel series of HBV capsid inhibitors that demonstrated promising cellular selectivity indexes, metabolic stabilities, and in vitro safety profiles. Herein we disclose the design, synthesis, structureactivity relationship (SAR), cocrystal structure in complex with HBV capsid proteins and in vivo pharmacological study of the 4-methyl HAP analogues. In particular, the (2S,4S)-4,4-difluoroproline substituted analogue 34a demonstrated high oral bioavailability and liver exposure and achieved over 2 log viral load reduction in a hydrodynamic injected (HDI) HBV mouse model.
I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 5908-62-3, help many people in the next few years.name: 1,1-Dioxo-isothiazolidine
Reference：
Quinuclidine – Wikipedia,
Quinuclidine | C7H584N | ChemSpider